Alector Inc
For the period ended Dec 31, 2023. Filed Feb 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 27, 2024
ALEC$2.46+7.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(In thousands, except share and per share data)
| December 31, | December 31, | |
|---|---|---|
| 2023 | 2022 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $74,555 | $154,323 |
| Marketable securities | 474,306 | 558,528 |
| Receivable from collaboration partner | — | 2,587 |
| Prepaid expenses and other current assets | 16,946 | 10,997 |
| Total current assets | 565,807 | 726,435 |
| Property and equipment, net | 21,861 | 25,521 |
| Operating lease right-of-use assets | 25,195 | 27,811 |
| Restricted cash | 1,546 | 1,472 |
| Other assets | 7,418 | 6,409 |
| Total assets | $621,827 | $787,648 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $3,775 | $4,189 |
| Accrued clinical supply costs | 5,215 | 5,559 |
| Accrued liabilities | 30,378 | 27,771 |
| Deferred revenue, current portion | 82,975 | 48,231 |
| Payable to collaboration partner | 7,703 | — |
| Refund liability to collaboration partner, current portion | 39,440 | — |
| Operating lease liabilities, current portion | 8,462 | 8,059 |
| Total current liabilities | 177,948 | 93,809 |
| Deferred revenue, long-term portion | 210,845 | 443,370 |
| Refund liability to collaboration partner, long-term portion | 67,047 | — |
| Operating lease liabilities, long-term portion | 30,456 | 35,268 |
| Other long-term liabilities | 1,373 | 759 |
| Total liabilities | 487,669 | 573,206 |
| Commitments and contingencies (Note 4) | ||
| Stockholders’ equity: | ||
| Common stock, $0.0001 par value; 200,000,000 shares authorized; 84,879,693 and 82,895,718 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively | 8 | 8 |
| Additional paid-in capital | 844,044 | 798,696 |
| Accumulated other comprehensive income (loss) | 184 | (4,575) |
| Accumulated deficit | (710,078) | (579,687) |
| Total stockholders’ equity | 134,158 | 214,442 |
| Total liabilities and stockholders’ equity | $621,827 | $787,648 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.